| 0 (0%) | 12-26 19:31 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 49.26 | 1-year : | 57.53 |
| Resists | First : | 42.17 | Second : | 49.26 |
| Pivot price | 39.15 |
|||
| Supports | First : | 37.69  |
Second : | 34.91 |
| MAs | MA(5) : | 40.1 |
MA(20) : | 39.22 |
| MA(100) : | 27.98 |
MA(250) : | 0 | |
| MACD | MACD : | 1.5 |
Signal : | 1.8 |
| %K %D | K(14,3) : | 58.8 |
D(3) : | 67.9 |
| RSI | RSI(14): 60.2 |
|||
| 52-week | High : | 42.17 | Low : | 14.59 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ CSTL ] has closed below upper band by 43.5%. Bollinger Bands are 41.4% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 9 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 39.97 - 40.3 | 40.3 - 40.52 |
| Low: | 38.6 - 38.96 | 38.96 - 39.2 |
| Close: | 38.92 - 39.48 | 39.48 - 39.86 |
Fri, 26 Dec 2025
How geopolitical tensions affect CSTL stock - Market Capitalization Trends & Reap the Rewards of Patience + Planning - Bollywood Helpline
Thu, 25 Dec 2025
Assessing Castle Biosciences (CSTL) Valuation After New Uveal Melanoma Data and Renewed Analyst Optimism - simplywall.st
Wed, 24 Dec 2025
What Makes Castle Biosciences (CSTL) a Good Fit for 'Trend Investing' - Nasdaq
Mon, 22 Dec 2025
Castle Biosciences (CSTL) Receives Analyst Rating Update with Ra - GuruFocus
Mon, 22 Dec 2025
Castle Biosciences (NASDAQ:CSTL) Given New $50.00 Price Target at Canaccord Genuity Group - MarketBeat
Mon, 22 Dec 2025
CCORF Maintains Castle Biosciences(CSTL.US) With Buy Rating, Raises Target Price to $50 - 富途牛牛
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
|
|
|
Sector:
|
|
|
Industry:
|
|
| Shares Out | 29 (M) |
| Shares Float | 27 (M) |
| Held by Insiders | 2.9 (%) |
| Held by Institutions | 92.3 (%) |
| Shares Short | 1,840 (K) |
| Shares Short P.Month | 1,550 (K) |
| EPS | -0.44 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 16.02 |
| Profit Margin | -3.6 % |
| Operating Margin | -8.2 % |
| Return on Assets (ttm) | -1.8 % |
| Return on Equity (ttm) | -2.7 % |
| Qtrly Rev. Growth | -3.3 % |
| Gross Profit (p.s.) | 9.4 |
| Sales Per Share | 11.76 |
| EBITDA (p.s.) | 0.26 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 62 (M) |
| Levered Free Cash Flow | 29 (M) |
| PE Ratio | -89.54 |
| PEG Ratio | 0 |
| Price to Book value | 2.45 |
| Price to Sales | 3.34 |
| Price to Cash Flow | 18.61 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|